Avantor, Inc. (NYSE:AVTR) Holdings Trimmed by Country Trust Bank

Country Trust Bank lowered its holdings in Avantor, Inc. (NYSE:AVTR) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,780,015 shares of the company’s stock after selling 59,597 shares during the period. Country Trust Bank’s holdings in Avantor were worth $37,505,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp lifted its position in Avantor by 58.0% in the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after buying an additional 8,206,695 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Avantor by 653.0% in the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock worth $159,740,000 after acquiring an additional 5,354,678 shares during the last quarter. FMR LLC raised its holdings in shares of Avantor by 557.2% during the third quarter. FMR LLC now owns 4,675,283 shares of the company’s stock worth $120,950,000 after acquiring an additional 3,963,912 shares in the last quarter. Janus Henderson Group PLC boosted its position in Avantor by 18.2% during the third quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after purchasing an additional 2,719,615 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in Avantor by 146.5% in the third quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock valued at $67,996,000 after purchasing an additional 1,562,018 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on AVTR shares. UBS Group reaffirmed a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Barclays reduced their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Wells Fargo & Company dropped their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Robert W. Baird reduced their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, Raymond James cut their target price on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.38.

Avantor Price Performance

NYSE AVTR opened at $22.22 on Friday. The stock has a 50-day simple moving average of $21.66 and a 200 day simple moving average of $23.43. Avantor, Inc. has a twelve month low of $19.59 and a twelve month high of $28.00. The stock has a market capitalization of $15.12 billion, a PE ratio of 48.29, a P/E/G ratio of 3.82 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.